Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Cisplatin Followed by Gemcitabine in Advanced NSCLC
NCT00424853Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2005
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Sanofi. Primary endpoint: Overall Response Rate. Started May 2005; status: completed.
02
Drugs
docetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00424853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00424853.